Balance of DNA methylation and demethylation in cancer development
Genome-wide 5-hydroxymethylome analysis of a rodent hepatocarcinogen model reveals that 5-hydroxymethylcytosine-dependent active DNA demethylation may be functionally important in the early stages of carcinogenesis.
See research article http://genomebiology.com/2012/13/10/R93
KeywordsHistone Mark Active Demethylation Somatic Cell Reprogram Complete Demethylation Cyp2b10 Promoter
thymine DNA glycosylase.
Epigenetic information is crucial for eukaryotic organisms as it impacts a broad range of biological processes from gene regulation to disease pathogenesis. This information is mainly embodied in DNA methylation, carried by 5-methylcytosine (5mC, the fifth base), and various histone modifications. It is well-established that epigenetics can play critical roles in cancer development; a highly distorted epigenome (including aberrant DNA methylation and histone modification patterns) is now accepted to be a general feature of many cancers [1, 2]. Understanding the molecular mechanisms of epigenetic alterations at the early stages of tumorigenesis may therefore be important in developing new cancer treatments.
A cell's DNA methylation pattern is a dynamic status balanced by methylation and demethylation, and aberrant DNA methylation has been attributed to either excessive methylation or deficient demethylation. A study by Meehan, Moggs and colleagues, published in this issue of Genome Biology , now links active demethylation with the early stages of carcinogenesis by investigating the non-genotoxic carcinogen phenobarbital (PB)-induced rodent hepatocarcinogen model.
Active DNA demethylation and 5-hydroxymethylcytosine
DNA methylation is established during early development and maintained through generations by DNA methyltransferases (DNMTs). DNA methylation can be erased during replication if DNMTs fail to methylate the daughter strand, a process named passive demethylation. However, in multiple instances, DNA demethylation in mammalian cells has been observed in the absence of DNA replication. The mechanisms for the active DNA demethylation pathways that must be at work in these non-replicating cells had been elusive for decades, until 5-hydroxymethylcytosine (5hmC) was identified as the so-called sixth base in 2009 [4, 5]. 5hmC is oxidized from 5mC by the TET (ten-eleven translocation) family of iron(II)/α-ketoglutarate-dependent dioxygenases, and is proposed to be a new epigenetic mark that constitutes the first step in an active pathway for DNA demethylation. Indeed, subsequent studies revealed that 5hmC can be further oxidized by TET enzymes to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC). 5fC and 5caC can be excised by thymine DNA glycosylase (TDG), and subsequently converted to cytosine through base excision repair, thus concluding the first biochemically validated active demethylation pathway in mammalian cells (for review, see ).
The aberrant DNA methylation landscape in cancer cells has long been imputed to the dysfunction of the methylation machinery, in the form of the DNMT enzymes. The discovery of 5hmC, 5fC and 5caC, however, prompts a re-evaluation of the relationship between DNA demethylation and cancer development, as it raises the possibility that impaired function of the demethylation machinery could equally lead to an imbalance and reprogramming of the DNA methylation status. Indeed, in human cancer cells, 5hmC is largely depleted compared with normal tissues, and the expression of TET genes is substantially reduced. Notably, TET2 is frequently mutated or inactivated in leukemia, but is required for normal hematopoiesis (for review, see ). Together, these recent observations suggested that functionally active demethylation is crucial in maintaining the dynamic balance of DNA methylation status and, as a consequence, in suppressing tumor development.
Active DNA demethylation and early carcinogenesis
While these recent studies linked the dysfunction of the active demethylation machinery to cancer, the detailed molecular mechanisms leading to carcinogenesis remained unclear. The new study by Meehan, Moggs and colleagues  now sheds light on the 5hmC-dependent active demethylation pathway during the early stages of hepatocarcinogenesis, by using a rodent model of non-genotoxic carcinogenesis with PB. PB-mediated tumor promotion is a well-characterized rodent model of non-genotoxic liver carcinogenesis, in which epigenetic alterations can be profiled at different stages. Using this model, the authors previously investigated DNA methylation changes in the mouse liver during a short term (28 days) exposure to PB, and discovered that 5mC levels only became reduced in the promoter regions of a small subset of PB-induced genes . Cyp2b10, a direct and early target of the PB-induced signaling pathway, exhibited both the strongest transcriptional upregulation and the most significant promoter demethylation, associated with a repressive-to-active switch of histone marks .
To further elucidate whether 5hmC is involved in PB-induced carcinogenesis, in the new study the authors use a genome-wide hMeDIP (hydroxymethylated DNA immunoprecipitation)-coupled microarray to profile the 5-hydroxymethylome in mouse liver, both before and after a 28-day PB exposure . These data represent the first report of the genome-wide distribution of 5hmC in mouse liver, which is found to be generally similar to those of mouse embryonic stem cells and cerebellum tissue, although some distinct features were also observed . The study goes on to investigate the relationship between the 5-hydroxymethylome and 5mC, histone marks and gene expression levels.
Following the 28-day PB treatment, the 5hmC signal in promoter proximal regions is elevated specifically in PB-induced genes, and this upregulation is reciprocal to decreases in the level of 5mC.
Returning to the previous study's focus on the Cyp2b10 promoter  the authors are able to confirm that its strong demethylation is associated with a significant increase in the level of 5hmC . This is an interesting example of apparent active demethylation through 5hmC at a specific locus. To further support the hypothesis that 5hmC acts as an intermediate of active demethylation in tumorigenesis, the authors track 5mC/5hmC changes at the Cyp2b10 promoter during a longer, 91-day PB exposure. This prolonged PB treatment leads to complete demethylation (loss of both 5mC and 5hmC) in the center of the promoter region, which resembles the general features of aberrant methylation and depleted 5hmC in cancer. Collectively, the data in this work suggest that a 5hmC-dependent active demethylation pathway is involved in the early stages of PB-induced carcinogenesis.
Perspectives and insights
An additional angle to pursue is whether 5hmC has an epigenetic function that directly regulates gene expression, rather than simply acting as a demethylation intermediate. In this regard, two very recent studies provide evidence for a hypothesis in which 5hmC itself can activate target genes. The first study showed that a 5mC regulatory enzyme (Parp1) and a 5hmC-generating TET enzyme (Tet2) functioned separately during somatic cell reprogramming, whereas redundancy would be expected were 5hmC simply to be an intermediate . In the second study, 5hmC regeneration was found to be a potent suppressor of melanoma progression .
Finally, the study by Meehan, Moggs and colleagues  may provide early biomarkers for cancer diagnostics and prognostics, although it must first be determined whether 5hmC changes during the early stages of carcinogenesis are recurring events in other non-genotoxic carcinogenesis exposure models. 5hmC holds promise not only in diagnostics, but also in therapeutics. Current epigenetic therapy efforts have mainly focused on targeting the DNA methylation and histone modification machineries, by using DNA methylation inhibitors and histone deacetylase inhibitors, respectively (Figure 1) . From the results described in , however, it is tempting to speculate that, in certain cases, using TET or TDG inhibitors to target the DNA demethylation machinery may also prevent cancer development (Figure 1).
We thank SF Reichard for editing the manuscript.
- 3.Thomson JP, Lempiäinen H, Hackett JA, Nestor CE, Müller A, Bolognani F, Oakeley EJ, Schübeler D, Terranova R, Reinhardt D, Moggs JG, Meehan RR: Non-genotoxic carcinogen exposure induces defined changes in the 5-hydroxymethylome. Genome Biol. 2012, 13: R93-10.1186/gb-2012-13-10-r93.PubMedPubMedCentralCrossRefGoogle Scholar
- 5.Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, Agarwal S, Maciejewski JP, Rao A: Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009, 324: 930-935. 10.1126/science.1170116.PubMedPubMedCentralCrossRefGoogle Scholar
- 8.Lempiäinen H, Müller A, Brasa S, Teo SS, Roloff TC, Morawiec L, Zamurovic N, Vicart A, Funhoff E, Couttet P, Schübeler D, Grenet O, Marlowe J, Moggs J, Terranova R: Phenobarbital mediates an epigenetic switch at the constitutive androstane receptor (CAR) target gene Cyp2b10 in the liver of B6C3F1 mice. PLoS One. 2011, 6: e18216-10.1371/journal.pone.0018216.PubMedPubMedCentralCrossRefGoogle Scholar
- 9.Doege CA, Inoue K, Yamashita T, Rhee DB, Travis S, Fujita R, Guarnieri P, Bhagat G, Vanti WB, Shih A, Levine RL, Nik S, Chen EI, Abeliovich A: Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2. Nature. 2012, 488: 652-655. 10.1038/nature11333.PubMedCrossRefGoogle Scholar
- 10.Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, Xu W, Tan L, Hu Y, Zhan Q, Lee CW, Hu D, Lian BQ, Kleffel S, Yang Y, Neiswender J, Khorasani AJ, Fang R, Lezcano C, Duncan LM, Scolyer RA, Thompson JF, Kakavand H, Houvras Y, Zon LI, Mihm MC, Kaiser UB, Schatton T, Woda BA, Murphy GF, et al: Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell. 2012, 150: 1135-1146. 10.1016/j.cell.2012.07.033.PubMedPubMedCentralCrossRefGoogle Scholar